03 / mRNA R&D
Eva
mRNA R&D AI Platform
Eva is the Agentic Innovation Platform applied to mRNA discovery and development. It compresses the work between candidate sequence and IND-enabling evidence — without compromising the regulatory rigour that makes mRNA development trustworthy.
Status — Eva is in active development. The demo below shows the platform’s current scope and direction.
Live demo · Eva
mRNA candidate prioritisation · campaign-007
MULTI-OBJECTIVE WEIGHTS
Adjust weights to re-rank the candidate set in real time.
RANKED CANDIDATES
- 0173.9
mRNA-α03
- 0272.2
mRNA-α05
- 0370.7
mRNA-α06
- 0469.6
mRNA-α01
- 0566
mRNA-α02
- 0665.7
mRNA-α04
Illustrative scoring across four objectives. The production platform configures the objective space per programme and maintains the full decision provenance.
A modality outpacing its infrastructure
mRNA has gone from a vaccine breakthrough to a platform modality across infectious disease, oncology, and rare disease. The science is moving faster than the supporting infrastructure for design, evidence assembly, and regulatory translation. Eva is built for that gap.
The platform applied to mRNA
Eva inherits the Agentic Innovation Platform’s GxP-compliant harness, traceability, and explainability — and configures them for the specific structure of mRNA R&D. Sequence design and screening. Construct prioritisation against multi-objective criteria. Pre-clinical evidence assembly. IND-enabling documentation. Adaptive design space management as candidates progress.
The team’s scientists supervise the work. Eva accelerates it. PACE evolves the team alongside the platform so that supervision remains sharp.